Athira Pharma, Inc. (ATHA)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Athira Pharma, Inc. (ATHA)
Company Performance

Current Price

as of Oct 18, 2024

$0.47

P/E Ratio

N/A

Market Cap

$18.16M

Description

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.

Metrics

Overview

  • HQBothell, WA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerATHA
  • Price$0.4725+5.54%

Trading Information

  • Market Cap$18.16M
  • Float92.11%
  • Average Daily Volume (1m)455,062
  • Average Daily Volume (3m)790,810
  • EPS-$2.97

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$26.86M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$27.79M
  • EV$2.97M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B0.22
Documents
SEC Filings
8-K (2024-10-18)
8-K (2024-10-07)
8-K (2024-09-17)
8-K (2024-09-03)
8-K (2024-08-01)
8-K (2024-05-29)
8-K (2024-05-17)
8-K (2024-05-15)
8-K (2024-02-22)
8-K (2024-01-08)
8-K (2023-11-09)
8-K (2023-08-10)
8-K (2023-05-22)
8-K (2023-05-11)
8-K (2023-03-23)
8-K (2023-01-06)
10-Q (2024-08-01)
10-Q (2024-05-15)
10-Q (2023-11-09)
10-Q (2023-08-10)
10-Q (2023-05-11)
10-K (2024-02-22)
10-K (2023-03-23)
Factset Street Account
Athira Pharma reports Q3 EPS ($0.87) vs FactSet ($0.81) [5 est, ($0.85)-(0.75)] ($1.39, 0.00) (2023-11-09T21:13:52Z)
Athira Pharma presents preclinical data further supporting the therapeutic potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS) ($1.80, 0.00) (2023-10-05T20:32:43Z)
Athira Pharma announces presentation of fosgonimeton preclinical data ($1.52, 0.00) (2023-11-15T13:19:23Z)
Earnings Calls
Earnings Report 2021Q4
Earnings Report (2022-03-24)